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ABSTRACT
Triple-negative breast cancer (TNBC) represents a more aggressive and difficult 
subtype of breast cancer where responses to chemotherapy occur, but toxicity is 
significant and resistance often follows. Immunotherapy has shown promising results 
in various types of cancer, including breast cancer. Here, we investigated a new 
combination strategy where histone deacetylase inhibitors (HDACi) are applied with 
immune checkpoint inhibitors to improve immunotherapy responses in TNBC.
Testing different epigenetic modifiers, we focused on the mechanisms underlying 
HDACi as priming modulators of immunotherapy. Tumor cells were co-cultured 
with human peripheral blood mononuclear cells (PBMCs) and flow cytometric 
immunophenotyping was performed to define the role of epigenetic priming in 
promoting tumor antigen presentation and immune cell activation. We found that 
HDACi up-regulate PD-L1 mRNA and protein expression in a time-dependent manner 
in TNBC cells, but not in hormone responsive cells. Focusing on TNBC, HDACi up-
regulated PD-L1 and HLA-DR on tumor cells when co-cultured with PBMCs and down-
regulated CD4+ Foxp3+ Treg in vitro. HDACi significantly enhanced the in vivo response 
to PD-1/CTLA-4 blockade in the triple-negative 4T1 breast cancer mouse model, the 
only currently available experimental system with functional resemblance to human 
TNBC. This resulted in a significant decrease in tumor growth and increased survival, 
associated with increased T cell tumor infiltration and a reduction in CD4+ Foxp3+ T 
cells in the tumor microenvironment. Overall, our results suggest a novel role for HDAC 
inhibition in combination with immune checkpoint inhibitors and identify a promising 
therapeutic strategy, supporting its further clinical evaluation for TNBC treatment.
INTRODUCTION
Breast cancer is one of the most common diseases, 
second only to lung cancer as the leading cause of cancer 
death in women, accounting for 30% of new diagnoses [1]. 
Triple-negative breast cancer (TNBC) is a heterogeneous 
subtype of breast cancer with poor prognosis and high 
risk of relapse. Despite initial response to therapy, 
resistance develops in the majority of patients [2]. Current 
approved therapeutic options for TNBC are limited to 
anthracyclines, taxanes and anti-metabolites [3].
Histone deacetylase inhibitors (HDACi) represent 
a new class of anticancer agents that induce a wide 
range of transient gene expression alterations, without 
www.impactjournals.com/oncotarget/         Oncotarget, 2017, Vol. 8, (No. 69), pp: 114156-114172
                                                     Research Paper
Oncotarget114157www.impactjournals.com/oncotarget
implicating permanent changes in DNA sequence [4, 5]. 
The cellular response to HDACi is complex and involves 
the regulation of histone and non-histone proteins by 
modifying their post-translational acetylation, thus 
playing a critical role in various cancer pathways. In 
addition to their effects on cancer signaling, HDACi 
have distinct immune modulatory functions, including 
modulation of regulatory T cells (Treg), Foxp3 expression 
and changes in tumor-infiltrating lymphocytes (TILs) 
composition [6, 7]. Emerging data suggest that epigenetic 
modulation is important for controlling T cells infiltration, 
differentiation, and PD-L1 expression [7-9].
In this context, the introduction of immunotherapy 
to cancer treatment is providing significant clinical benefit 
against immunogenic tumors, such as melanoma [7, 10] 
and has created high hopes for TNBC treatment. Antigen-
specific immune responses are complex and highly 
regulated, involving stimulatory/inhibitory coupling of 
receptors and ligands that can be specifically directed 
against cancer cells [11]. The PD-1/PD-L1 pathway is 
a key inhibitory pathway [12, 13]. When activated, it 
regulates cytotoxic T cells activity and helps to avoid 
autoimmunity and maintain immune system homeostasis 
[14, 15]. In the tumor microenvironment, cancer exploits 
this pathway to suppress immune response and inhibit 
cytotoxic T cells activity.
In breast cancer, PD-L1 expression is primarily 
found in Her2+ and TNBC. Increased PD-L1 expression 
correlated with higher TILs, which are in turn associated 
with a decreased rate of recurrence, better response, better 
survival and stronger cytotoxic immune response [16, 
17]. PD-L1 over-expression in basal breast tumors has 
also been associated with increased expression of immune 
response related genes, with pathways that are involved 
in T cells activation, differentiation and expression 
of anti-tumor cytokines and with better response to 
anthracycline-based neoadjuvant chemotherapy [18, 19]. 
Thus, inhibition of PD-1/PD-L1 interactions may prevent 
T cells suppression and reactivate immune-surveillance.
Although HDAC inhibition has been reported to 
increase PD-1 blockade efficacy in melanoma and lung 
adenocarcinoma [9, 20], its potential role in breast cancer 
as immune modulator and the mechanism promoting such 
strategy has not been investigated. Additionally, PD-L1 
expression as a predictive marker for checkpoint inhibitors 
response has not been clearly established in breast cancer. 
Compared to lung cancer and melanoma, breast cancer 
appears less immunogenic, which may explain the 
relatively low response rate to single agent pembrolizumab 
[21]. Given the limited response to immunotherapy, we 
explored the potential of epigenetic modulation with 
HDACi to boost response to immune checkpoint inhibitors 
in both estrogen receptor-negative (ER-) and ER+ breast 
cancer. We found that HDAC inhibition leads to PD-
L1 up-regulation on tumor cells and pre-requisite cell 
surface expression. Only seen in ER- cell lines, PD-L1 up-
regulation was associated with increased HLA-DR tumor 
cells expression, CD4+ Foxp3+ CTLA-4high Treg down-
regulation in vitro, increased T cells tumor infiltration, 
longer survival and tumor growth inhibition in vivo. Taken 
together, our data suggest that HDACi potentiate immune 
checkpoint inhibitor blockade in TNBC.
RESULTS
HDACi up-regulate PD-L1
Multiple human breast cancer cell lines, which 
represent the molecular diversity of breast cancer, were 
tested for basal PD-L1 expression (Supplementary 
Figure 1A).
Expression varied significantly. Triple-negative 
MDA-MB231 cells exhibited the highest basal level of 
PD-L1 protein and mRNA, while MCF-7 cells (ER+, PR+ 
and HER2+) the lowest. Although SKBR3 cells (ER-, PR-, 
HER2+) expressed more PD-L1 mRNA than T47D cells 
(ER+, PR+, HER2-), protein expression was comparable 
(Supplementary Figure 1A and 1B).
To investigate PD-L1 modulation by HDACs, 
several breast cancer cell lines were treated with increasing 
doses of vorinostat. A dose-dependent up-regulation of 
PD-L1 protein expression was detected after 48 hours of 
treatment, which differed significantly between ER- versus 
ER+ breast cancer cells (Figure 1A). These effects were 
observed with class non-specific HDACi (vorinostat and 
panobinostat), but also with class specific HDACi such as 
valproic acid (VPA) and entinostat (Figure 1B). A relative 
quantification between western blot experiments is shown 
in Supplementary Figure 2. Moreover a time-dependent 
increase in PD-L1 mRNA was observed with various 
HDACi, comparable in trend to protein modulation 
(Figure 1C).
HDACi up-regulate cell surface PD-L1 
expression inTNBC cells
We then investigated the mechanism of HDACi-
mediated induction of PD-L1 and its cellular localization 
in triple-negative MDA-MB231 cells, characterized by 
higher basal expression and a significant increase of PD-
L1 after HDACi treatment. Like for GADD45a, a gene up-
regulated by HDACi at the transcriptional level [22], the 
HDACi-mediated increase of PD-L1 mRNA was blocked 
by concurrent treatment with the transcriptional inhibitor 
actinomycin-D, suggesting a transcriptional effect of 
HDACi (Figure 2A).
HDACi effect on PD-L1 expression was compared 
to other epigenetic drugs including azacitidine, a DNA 
methyltransferase inhibitor (DNMTi) and GSK126, a EZH2 
methyltransferase inhibitor. Combination treatment of 
vorinostat and azacitidine resulted in a greater up-regulation 
of PD-L1 mRNA expression (Figure 2B). The addition of 
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GSK126 enhanced the effect of vorinostat, but to a much 
lower extent compared to the DNMTi (Figure 2B).
To identify HDAC isoforms involved in PD-L1 
modulation, we treated MDA-MB231 cells with HDAC1, 
HDAC2, HDAC3, or HDAC6 siRNAs. Neither HDAC1, 
HDAC2, HDAC3 single silencing, a combination of the 
three, nor HDAC6 silencing resulted in increased PD-L1 
transcript in MDA-MB231 cells (Supplementary Figure 
3A). Although, a clear interpretation of these results is 
complicated as HDACs silencing involves non-specific 
and compensatory effects that could affect the results 
obtained (Supplementary Figure 3B and previous reports 
[23, 24]). This suggests that the regulation of PD-L1 in 
MDA-MB231 cells involves multiple HDAC enzymes and 
illustrates their redundant activity.
As a cell surface marker, PD-L1 is transported 
to the cell membrane to carry out its function [25]. 
To test whether HDACi-mediated PD-L1 modulation 
resulted in increased cell surface expression, cells were 
evaluated by immunofluorescence microscopy. Treatment 
of MDA-MB231 cells with vorinostat (1.5 μM) for 
48 hours increased the expression of PD-L1 protein 
Figure 1: HDACi modulate PD-L1 expression in ER- breast cancer cell lines in a dose- and time-dependent manner. 
(A) PD-L1, acetyl-H3 (AcH3) and acetyl-H4 (AcH4) protein expression was determined by western blot in MDA-MB231, SKBR3, T47D 
and MCF-7 cells untreated or treated for 24, 48 and 72 hours with increasing doses of vorinostat. (B) PD-L1, AcH3, AcH4 protein expression 
was evaluated in MDA-MB231, SKBR3, T47D and MCF-7 cells untreated or treated for 48 hours with different HDACi: valproic acid 
(VPA), panobinostat and entinostat. (C) PD-L1 mRNA expression was evaluated by qReal-Time PCR in MDA-MB231, SKBR3, T47D and 
MCF-7 cells untreated or treated with various HDACi for 6, 10 and 24 hours. β-actin was used as protein loading control in western blot or 
housekeeping control gene to normalize qReal-Time PCR reactions.
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(Figure 2C). In contrast, in MCF-7 cells, surface PD-
L1 was not detected before or after vorinostat treatment 
(Supplementary Figure 4A), consistent with the modest 
basal and HDACi-mediated expression, previously shown 
(Figure 1). To confirm the increased PD-L1 expression 
on the cell membrane, cells were treated with vorinostat, 
stained for PD-L1 antibody before or after cell membrane 
permeabilization and assessed by flow cytometry for 
PD-L1 expression in live cells. Autofluorescence was 
determined by the use of fluorescence minus one (FMO) 
control. The mean fluorescent intensity (MFI) of PD-L1 
expression was determined and, once autofluorescence 
Figure 2: Vorinostat induces PD-L1 expression in breast cancer cell lines directly at a transcriptional level and this 
translates to increased PD-L1 expression on the cell surface. (A) MDA-MB231 cells were untreated or treated with vorinostat 
(1.5μM) and/or actinomycin D (AD 5μg/mL) for 10 hours. The expression levels of PD-L1 and GADD45a mRNA were determined by 
qReal-Time PCR. (B) MDA-MB231 were untreated or treated with vorinostat (1.5μM) alone or in combination with azacitidine (Aza 
2μM) or GSK126 (GSK 300nM). PD-L1 mRNA expression was evaluated by qReal-Time PCR with β-actin used as housekeeping control 
gene. (C) MDA-MB231 cells untreated or treated with vorinostat (1.5μM) for 48 hours, were fixed, stained for PD-L1 (red) and DAPI for 
nuclei (blue) and observed by microscope. Representative images show PD-L1+ cells with 20x or 40x magnification. (D) MDA-MB231 
untreated or treated with increasing doses of vorinostat for 24 and 48 hours were collected for flow cytometry analysis: cells were stained 
for PD-L1 before or after fixation/permeabilization steps to distinguish between surface and intracellular markers staining, respectively. 
Flow cytometric quantification of PD-L1 MFI in live tumor cells is shown (expressed as fold change relative to the control). Statistical 
comparisons are relative to respective intracellular or surface control. Statistical significance is indicated by p-values as * P ≤ 0.05; ** P ≤ 
0.01; *** P ≤ 0.001; **** P ≤ 0.0001 and ns: non significant. Data are presented as the mean ± SD for (A) and (B) and ± SEM for (D).
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MFI values were subtracted, the adjusted MFI values 
were graphed. Vorinostat increased PD-L1 MFI in both 
permeabilized and unpermeabilized cells, consistent 
with HDACi-mediated PD-L1 up-regulation resulting in 
increased cell surface expression (Figure 2D).
In its initial identification, the PD-1 gene was 
suggested to be associated with programmed cell death 
induction [26]. To confirm that the PD-L1 up-regulation 
we observed upon vorinostat treatment was not associated 
with an apoptotic effect, we compared the effect of 
vorinostat to the well-established apoptotic-inducing 
agent, epirubicin. Notably, epirubicin treatment was 
not associated with PD-L1 induction (Supplementary 
Figure 5). Importantly, the PD-L1 up-regulation we 
observed after vorinostat treatment, at the doses used in 
our study, was not associated with an apoptotic effect, 
as demonstrated by the absence of PARP cleavage 
(Supplementary Figure 5B).
Vorinostat effect on tumor cells co-cultured 
with human peripheral blood mononuclear cells 
(PBMCs)
We further confirmed that PD-L1 expression was 
enhanced with vorinostat treatment in a dose- and time-
dependent manner (Figure 3A).
To play an active role in tumor escape, PD-1, 
expressed by TILs, must engage with PD-L1, on tumor 
cells surface. Since the interaction between these two cell 
types in the tumor microenvironment is necessary for the 
downstream function of the PD-1 pathway, we investigated 
the effect of HDACi on tumor cells in the presence of 
immune cells. MDA-MB231 cells were exposed to 
vorinostat (1.5μM) up to 72 hours either alone or co-
cultured with human PBMCs from healthy donors. Tumor 
cells and PBMCs co-cultured or cultured individually were 
evaluated by flow cytometry with a multiparameter panel 
to assess CD45, CD3, CD4, CD8 and Foxp3 expression 
(Supplementary Figure 6). Additionally, we quantified 
markers associated with immunotherapy response and 
prognosis in melanoma patients [27, 28], such as PD-1, 
PD-L1, CTLA-4 and major histocompatibility complex 
(MHC) class-II HLA-DR. Following vorinostat treatment, 
PD-L1 expression was increased in MDA-MB231 cells, 
which was unaffected by co-culturing with PBMCs (Figure 
3B and 3C). Furthermore, these triple-negative cells 
exhibited a dose-dependent induction of HLA-DR after 
48 hours of vorinostat treatment (Figure 3D), which was 
unaffected by co-culture with PBMCs (Figure 3E and 3F).
MCF-7 cells treated with vorinostat exhibited a 
modest increase of PD-L1, which was negligibly effected 
by co-culturing with PBMCs (Supplementary Figure 4B 
and 4C). In contrast to MDA-MB231 cells, vorinostat 
treatment reduced HLA-DR expression in MCF7 cells 
over time, which was further reduced when co-cultured 
with PBMCs (Supplementary Figure 4D and 4E).
Vorinostat activity on T cells co-cultured with 
tumor cells
In addition to affecting cell surface expression 
of immune modulators on tumor cells, HDACs play 
a significant role in regulating immune-related genes. 
Foxp3 is critical for Treg development and its expression 
is modulated by epigenetic modifications [7]. Vorinostat 
treatment significantly reduces Foxp3+ CTLA-4high Treg in 
PBMCs cultured alone and together with MDA-MB231 
cells (Figure 3G and 3H). When co-cultured with MDA-
MB231 cells, the percentage of CD4+ Foxp3+ CTLA-4high 
T cells in PBMCs was higher than in PBMCs cultured 
alone. Addition of vorinostat to co-cultured MDA-MB231 
cells and PBMCs attenuated this increase (Figure 3G 
and 3H) and reduced the total number of Foxp3+ CTLA-
4high expressing cells (Figure 3I). A reduced percentage 
of CD4+ Foxp3+ CTLA-4high T cells in PBMCs was also 
observed when PBMCs were co-cultured with MCF-7 
cells (Supplementary Figure 4F).
To better characterize the effects of vorinostat on 
PBMCs in regard to the Treg population, we performed 
a second analysis using a more comprehensive flow 
cytometry panel that includes the Treg signature markers 
CD25, CD127, Foxp3 and CTLA-4. 3x106 PBMCs cells, 
obtained from healthy donors, were cultured with or 
without vorinostat (1.5μM) up to 48 hours. Treg were 
identified in the live CD4+ gate by high co-expression of 
CD25, Foxp3 and CTLA-4 and low expression of CD127. 
Using this gating strategy, Treg were significantly reduced 
upon vorinostat treatment (Figure 3J and 3K).
Vorinostat activity on MCF-7 tamoxifen-
resistant cells
Consistent with previous reports [19], we found 
that ER+ breast cancer cells have limited PD-L1 
expression (Supplementary Figure 1). To further explore 
the relationship between HDACs function and PD-L1 
expression in ER+ breast cancer, we investigated PD-L1 
expression in a tamoxifen-resistant ER+ breast cancer cell 
line originated from MCF-7 (MCF-7 TamR) [29]. MCF-7 
TamR cells expressed a higher baseline level of PD-L1 
mRNA compared to its parental cells (Supplementary 
Figure 1B and 1D). Exposure of the resistant cells 
to vorinostat resulted in a modest increased PD-L1 
protein expression (Figure 4A and 4B), associated with 
an induction of PD-L1 expression at a transcriptional 
level (Figure 4C). Differently from ER- MDA-MB231 
cells, a modest, almost undetectable, increase of PD-L1 
expression was observed on the cell surface of MCF-7 
TamR cells, upon vorinostat treatment for 48 hours (Figure 
4D). In addition, a similar modest increase in PD-L1 MFI 
was observed when MCF-7 TamR cells were co-cultured 
with PBMCs from healthy donors (Figure 4E). In contrast 
to MDA-MB231, vorinostat treatment significantly 
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Figure 3: Vorinostat effect on TNBC cells and PBMCs co-cultured together. (A) MDA-MB231 cells untreated or treated 
with increasing doses of vorinostat were collected 24 and 48 hours after treatment and stained for flow cytometry analysis to quantify 
PD-L1 expression (expressed as fold change relative to the control). Statistical comparisons are relative to respective control at 24 or 48 
hours. (B) MDA-MB231 cells were cultured alone or in presence of PBMCs obtained from healthy donors. Cells were untreated or treated 
with vorinostat (1.5μM) for 24, 48 and 72 hours and then collected and stained with a comprehensive multicolor flow cytometry panel. 
Representative flow cytometric plot for PD-L1 expression in MDA-MB231 with or without vorinostat treatment. (C) Flow cytometric 
quantification of PD-L1 expression (expressed as fold change relative to the control) in MDA-MB231 cells alone or co-cultured with 
PBMCs with or without vorinostat treatment. (D) Flow cytometric quantification of HLA-DR expression (expressed as fold change relative 
to the control) in MDA-MB231 cells treated or untreated with increasing doses of vorinostat for 24 and 48 hours. Statistical comparisons 
are relative to respective control. (E) Representative flow cytometric plot for HLA-DR expression in MDA-MB231 with or without 
vorinostat treatment. (F) Flow cytometric quantification of HLA-DR expression (expressed as fold change relative to the control) in 
MDA-MB231 cells alone or co-cultured with PBMCs with or without vorinostat treatment. (G) Representative flow cytometric plots for 
Foxp3+ CTLA-4high cells in PBMCs with or without vorinostat treatment. (H) Flow cytometric quantification (expressed as fold change 
relative to the control) of CD4+ Foxp3+ CTLA-4high T cells in PBMCs from healthy donors alone or in presence of MDA-MB231 after 24, 
48 and 72 hours of vorinostat treatment. (I) Flow cytometric quantification of the number of CD4+ Foxp3+ CTLA-4high T cells in PBMCs 
with or without vorinostat treatment for 24, 48 and 72 hours. (J) Representative flow cytometric plots for CD25/CTLA-4 co-expression 
in live CD4+, CD127low, Foxp3+ PBMCs with or without vorinostat treatment. (K) Flow cytometric quantification of CD25high CTLA-4high 
Treg in PBMCs of healthy donors with or without vorinostat treatment for 24 and 48 hours. Plots in (J) and (K) are pre-gated on live CD4+ 
CD127low Foxp3+ cells. Data are presented as the mean ± SEM. Statistical significance is indicated by p-values as * P ≤ 0.05; ** P ≤ 0.01; *** 
P ≤ 0.001; **** P ≤ 0.0001.
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reduced HLA-DR expression on MCF-7 TamR cells in 
the co-culture system, as observed for the parental MCF-
7 cells (Figure 4F and Supplementary Figure 4E). This 
suggests a distinct and opposing effect of HDACi in ER+ 
and ER- cells. Instead, even in the presence of MCF-7 
TamR, as for the parental cells, we observed a reduction in 
Foxp3+ CTLA-4high Treg upon vorinostat treatment (Figure 
4G and Supplementary Figure 4F).
HDACi-mediated increase of PD-L1 in mouse 
breast cancer cells
To test in vivo our hypothesis of HDACi as immune-
priming agents, we tested PD-L1 expression in different 
mouse breast cancer cell lines following treatment with 
various HDACi. HDACi modulates PD-L1 expression in 
the mouse metastatic 4T1 and EMT6 breast cancer cells. 
Figure 4: HDACi effect on tamoxifen-resistant MCF-7 breast cancer cells. (A) MCF-7 TamR cells were untreated or treated with 
increasing doses of vorinostat; PD-L1 and acetyl-H3 protein expression was evaluated at 24, 48 and 72 hours after treatment by western blot 
analysis. (B) PD-L1 protein expression was evaluated by western blot in MCF-7 TamR cells exposed to VPA, panobinostat and entinostat 
for 48 hours. (C) PD-L1 mRNA expression was quantified by qReal-Time PCR in MCF-7 TamR cells after treatment with different HDACi. 
β-actin was used as protein loading control in western blot and housekeeping control gene to normalize qReal-Time PCR reactions. (D) 
MCF-7 TamR cells, untreated or treated with increasing doses of vorinostat for 24 and 48 hours, were collected for flow cytometry analysis, 
as described in the Material and Methods, to distinguish between surface and intracellular PD-L1 expression. Flow cytometric quantification 
of PD-L1 MFI for live tumor cells (expressed as fold change relative to the control) is shown. Flow cytometric quantification of PD-L1 (E) 
and HLA-DR (F) expression in MCF-7 TamR cells alone or co-cultured with PBMCs and evaluated at 24, 48 and 72 hours after treatment 
with vorinostat (1.5μM). (G) Flow cytometric quantification of CD4+ Foxp3+ CTLA-4high T cells in PBMCs of healthy donors alone or in 
presence of MCF-7 TamR cells after 24, 48 and 72 hours of vorinostat treatment. Statistical significance is indicated by p-values as * P ≤ 
0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001. Data are presented as the mean ± SD for (C) and ± SEM for (D-G).
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In contrast, PD-L1 down-regulation or no effect was 
seen in JC mouse breast cancer cells following HDACi 
treatments (Supplementary Figure 7A). Consistent 
with human breast cancer cells (Figure 2B), PD-L1 up-
regulation was increased when vorinostat was combined 
with azacitidine in the 4T1 and EMT6 mouse cell lines 
(Supplementary Figure 7B).
In vivo antitumor effect of vorinostat in 
combination with immunotherapy
To evaluate the potential interaction of HDACi to 
prime immunotherapy in vivo, the highly proliferative and 
resistant 4T1 mouse breast cancer cell line was chosen, the 
only known mouse cell line with similar immunogenicity, 
Figure 5: Anti-tumor activity of vorinostat, anti-PD-1 and anti-CTLA-4 on established mouse breast cancer allografts. 
(A) 4T1 cells (1 x 106) were s.c. injected into BALB/C mice. When established tumors were palpable, mice were treated with vorinostat 
(100 mg/kg i.p.), anti-PD-1 (10 mg/Kg i.p.) combined with anti-CTLA-4 (10mg/Kg i.p.) or a combination of the three drugs as described 
in the Material and Methods. Relative tumor volume curves for 4T1 allograft; measurements are shown as mean ± SEM tumor volume (n 
= 8). (B) Tumor volume averages from each group at day 0 and day 25 (end of treatment) were compared and presented as percentages of 
vehicle. (C) Effect of vorinostat and/or anti-PD1 + anti-CTLA-4 treatments on the survival of 4T1 allograft mice. (D) Mouse PD-L1 mRNA 
was measured in FFPE 4T1 tumor samples by RNAscope assay. Hybridization signals were amplified and visualized with RNAscope 2.0 
HD detection kit. Data are presented as the mean ± SEM. (E) Murine PD-L1 RNAscope images were captured under a bright field at 40x 
magnification. One representative image for each treatment is shown. Positive signals showed as brown punctuate dots were analyzed by 
scoring with ImageJ software. Statistical significance is indicated by p-values as * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001; Ns: 
non significant.
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metastatic properties and growth characteristics as 
TNBC [30]. To induce tumor formation, 4T1 cells were 
subcutaneously implanted in BALB/c mice. Once tumors 
formed, mice were randomly assigned to receive doses 
of vorinostat, anti-PD-1 (a-PD-1) blockade, both drugs, 
or the vehicle as a control. A significant benefit was not 
observed when vorinostat was combined to the anti-PD-1 
blockade in regard to tumor growth or survival compared 
to single-drug treatment (Supplementary Figure 8A and 
8B). This is consistent with previous reports showing that 
the 4T1 tumor model is highly resistant to most therapeutic 
strategies, including checkpoint inhibitor blockade [30-32].
In order to overcome this resistance and to achieve a 
wider immune-modulatory effect, anti-CTLA-4 (a-CTLA-4) 
blockade was added to the therapeutic regimen to better 
represent what has been described in clinic. Indeed, even 
if both PD-1 and CTLA-4 function as T cells negative 
regulator, emerging data point to their non-redundant role in 
modulating immune response [12, 33]. Mice were injected 
with vorinostat, a combination of anti-PD-1 and anti-CTLA-4 
blockades, the three drugs in combination, or the vehicle 
as a control and tumor volume and percent change were 
measured (Figure 5A and 5B). The addition of anti-CTLA-4 
to the anti-PD-1 blockade induced a significant inhibition 
of tumor growth compared to single-agent treatment, 
which was significantly improved by vorinostat addition 
(Supplementary Figure 8A and Figure 5A). Vorinostat, the 
immunotherapy combination (a-PD-1 + a-CTLA-4) and 
the three-drugs combination reduced the tumor burden by 
12.5%, 34% and 88.5%, respectively (Figure 5B). Although 
repeated treatment with anti-CTLA-4 and anti-PD-1 as 
single-agent retarded tumor growth, tumor eradication was 
only observed when the HDACi was combined with the 
immunotherapy treatment. This synergistic interaction of the 
three drugs resulted in a significant survival increase (Figure 
5C). Notably, the combined treatment was well tolerated 
(Supplementary Figure 8C).
Pharmacodynamic effects in allograft tumors
Following treatments, tumors were harvested 
and evaluated. PD-L1 tumor expression was evaluated 
by RNA in situ hybridization analysis on formalin 
fixed paraffin embedded (FFPE) tissues. Indeed PD-
L1 immunohistochemistry (IHC) implicates several 
divergences in results interpretation, due to the absence of 
standardization and universal definition of positive cut-off, 
specificity and reproducibility of the available antibodies. 
Consistent with in vitro data, a significant PD-L1 mRNA 
up-regulation was observed with vorinostat treatment, 
further increased in tumors treated with the three-drug 
combination (Figure 5D and 5E).
Insufficient TILs and CD8+ T cells tumor infiltrate 
is recognized as one of the mechanism involved in 
immunotherapy resistance. We hypothesized that 
increasing T cells infiltration into tumors could be an 
efficacious strategy to enhance immunotherapy response. 
Thus, the number of CD4+ and CD8+ T cells was quantified 
in the tumors by IHC. Tumors treated with vorinostat had 
significantly more CD4+ T cells compared to the vehicle 
group, which was further increased in the presence of 
immunotherapy (Figure 6A and 6F).
CD4+ T cells commonly include Treg and 
conventional T helper (Th) cells. While Th cells control 
adaptive-immunity releasing cytokines that activate other 
effector immune cells against pathogens and cancer, Treg 
are suppressor T cells that modulate the immune system 
by suppressing induction and proliferation of effector T 
cells [34]. As Treg presence in tumors is associated with 
a poor prognosis [35], Foxp3 expression was evaluated 
in tumors to differentiate the increase in CD4+ T cells 
from an increase in Treg. Immunofluorescence staining 
of Foxp3 showed that vorinostat decreased the number 
of Foxp3+ cells, whereas the addition of immunotherapy 
had no effect (Figure 6B and 6G). In contrast, we found 
an increase in CD8+ T cells after vorinostat treatment 
that was further induced in tumors receiving the triple-
combination treatment, consistent with an induction of 
cytotoxic T lymphocytes in the tumor microenvironment 
(Figure 6C and 6H).
Tumor proliferation and survival were evaluated 
to determine the impact of HDACi on tumor growth. 
Vorinostat treatment induced a significant reduction in 
the number of mitotic cells alone and in combination 
with immunotherapy (Figure 6D). This was associated 
with a decrease in Ki67 expression. Indeed a trend in 
the reduction of Ki67 was found when vorinostat was 
administrated alone or in combination (Supplementary 
Figure 9A). A significant increase of apoptosis was 
observed by TUNEL assay in tumors receiving vorinostat 
compared to those receiving vehicle, which was further 
intensified when combined with immunotherapy (Figure 
6E and 6I). The percentage of necrotic cells was not 
significantly different in tumors receiving vorinostat 
compared to the combined treatment (Supplementary 
Figure 9B).
Taken together these data confirmed the in vitro 
findings that PD-L1 modulation by HDACi is associated 
with increased TILs in the tumour microenvironment, 
which could explain the increased efficacy observed in 
the combination treatment in vivo.
DISCUSSION
Immune checkpoint inhibitors activate exhausted 
T cells in several type of cancer, including TNBC [36]. 
Although they have been successfully integrated in the 
treatment of cancer, their role and optimal placement in 
breast cancer remains uncertain. Several reports have 
linked higher PD-L1 expression in breast cancer to better 
response and survival [16-19].
Although the presence of PD-L1 may enrich for 
response, in breast cancer this may not be sufficient. 
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Previous reports have shown that HDACi modulate 
immune response, alter Treg activity and regulate cytokine 
expression [6, 7, 37, 38]. In this study, we report a rational 
and innovative therapeutic approach in breast cancer that 
combines immunotherapy with HDACi, which acts in part 
by priming anti-tumor immune response. Our data suggest 
that HDACi mediated up-regulation of PD-L1 and HLA-
DR in TNBC may promote tumor recognition through the 
T cell receptor, thus enhancing the immune response.
Tumors evade immune surveillance by acquiring 
immunosuppressive phenotypes, modifying immune 
checkpoint pathways, recruiting Treg and avoiding 
cytotoxic T cells and antigen presenting cells recognition 
of the tumor cells. MHC class-I and –II are responsible for 
these interactions and their down-regulation is associated 
with immune suppression, poor prognosis and metastatic 
progression. In particular, HLA-DR has an important 
role in Th/inducer lymphocytes proliferation and low 
HLA-DR expression in breast cancer is associated with a 
mechanism of escape from Th-mediated immune response 
and increased tumor metastasis [39]. HLA-DR expression 
was found to be a promising positive predictive factor 
in node-negative breast cancer [40]. Similar results were 
found in colorectal cancer and in melanoma, where 
HLA-DR expression was associated with therapeutic 
response to immunotherapy, better progression free 
survival, overall survival (OS) and CD4+ and CD8+ T 
cells tumor infiltrate [28, 41]. MHC-II+ epithelial cells 
can present antigen to CD4+ Th cells and thus, promoting 
the expression of HLA-DR in tumor cells with HDACi, 
Figure 6: Effect of vorinostat/immunotherapy treatment on immune cell subset, proliferation and apoptosis in 4T1 
allograft tumors. Paraffin-embedded tissues were generated from each tumor for IHC and immunofluorescence analysis. Slices were 
stained for CD4 (A), Foxp3 (B) and CD8 (C) by IHC or immunofluorescence. Mitotic counts (D) were performed on H&E-stained sections, 
while apoptosis was measured by TUNEL assay (E). Data are presented as the mean ± SEM. Statistical significance is indicated by p-values 
as * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001; Ns: non significant. Representative image for CD4 (F), Foxp3 (G), CD8 (H), and 
TUNEL assay (I) are shown. Images were captured with a 40x objective on a light microscope. Scale bars correspond to 20μm. Scale bars 
correspond to 20μm.
Oncotarget114166www.impactjournals.com/oncotarget
may promote anti-tumor immunity and tumor suppression 
as an adaptive response.
Our in vivo data show that vorinostat combined with 
immune checkpoint inhibitors decreased overall tumor 
growth, prolonged survival and, in some cases, completely 
eradicated the tumor. We postulate that the therapeutic 
benefit observed in our study is a consequence of 
vorinostat-induced increase in tumor cells immunogenicity 
through HLA-DR up-regulation, associated with increase 
in T cells recognition, function and activation by anti-
PD1 and anti-CTLA-4 blockades. Our in vivo studies 
further show the relative ineffectiveness of PD-1 
blockade alone and the necessity to co-inhibit both the 
PD-1 and CTLA-4 pathway to have a significant anti-
tumor effect. This is consistent with a recent study where 
the success of anti-PD1 strategy requires the CD28/B7 
pathway co-stimulatory function [42]. Blocking CTLA-
4 may be necessary to allow CD28-dependent CD8+ T 
cells activation and proliferation after PD-1 blockade 
[42]. Furthermore, HDAC inhibition decreases Foxp3 
Figure 7: Hypothetical mechanism by which HDACi potentiate checkpoint inhibitors treatment in TNBC. HDACi are 
responsible for multiple different effects: on one side they induce anti-proliferative and pro-apoptotic effects on tumor, while they induce 
PD-L1 and HLA-DR expression on tumor cells, making the tumor more susceptible for tumor-antigen recognition. On the other hand, 
HDACi increase CD4+ and CD8+ T cell tumor infiltration and reduce the frequency of Treg in the tumor microenvironment.
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expression in CD4+ T cells, which may increase an anti-
tumor immune response by down-regulating suppressive 
Treg activity. Several reports have linked the increased 
Treg presence in breast tumors with an invasive phenotype 
and diminished OS [43-45]. Significant reduction in 
primary and metastatic tumor progression was obtained 
with Treg ablation in an oncogene-driven mammary 
carcinoma [46]. Moreover, increased frequency and 
higher proliferative activity of Treg has been correlated 
with higher tumor grade breast cancer [47]. These reports 
corroborate the importance of our finding and, together 
with HDACi-dependent promotion of T cells infiltration 
in the tumor microenvironment, may explain the increased 
efficacy of this combinational strategy.
CCL5 is a potent chemotactic for T cells, monocytes 
and eosinophils and plays an active role in recruiting 
leukocytes into inflammatory sites [48]. Highly expressed 
in various tumors, CCL5 promotes tumor growth 
and metastasis by inducing tumor cell proliferation, 
angiogenesis and matrix metallo-proteinases in breast 
cancer [48, 49]. CCL5 was found to reduce anti-tumor 
immune response by increasing the presence of tumor-
associated macrophages and Treg [49, 50]. A previous 
report demonstrated that the HDACi romidepsin enhances 
response to PD-1 blockade in lung cancer by inducing 
the expression of CCL5, CXCL9 and CXCL10, and thus 
enhancing T cells infiltration [20]. Conversely, another 
report in colorectal cancer associated a higher expression 
of CCL5 with a greater number of Treg and increased 
CD8+ T cells apoptosis, suggesting a critical role for CCL5 
in recruiting Treg and enhancing their ability to suppress 
CD8+ T cells [49]. We found that MDA-MB231 cells 
were characterized by a very low, almost undetectable, 
expression of CXCL9 and CXCL10 mRNA, only 
modestly affected by HDAC inhibition (data not shown), 
whereas the HDACi induced a significant down-regulation 
of CCL5 (Supplementary Figure 10). We believe that 
this may be linked to the reduction of CD4+ Foxp3+ cell 
infiltration observed in our study, as also postulated by 
others [49].
Opposite to the effects seen in TNBC cells, PD-
L1 basal expression was low in ER+ breast cancer and 
was only modestly up-regulated with treatment. This 
effect did not translate in PD-L1 up-regulation on ER+ 
cells surface (Figure 4D and Supplementary Figure 
4A). Furthermore, HLA-DR was down-regulated, which 
would further support the non-immunogenic behavior 
of ER+ cells. Hormone responsive tumors are, indeed, 
known to be less immune response driven [36]. PD-L1 
baseline expression was more pronounced in the ER+ 
tamoxifen-resistant cells, but its expression was modestly 
increased with HDAC inhibition, not at the cell surface 
level, and yet not associated with HLA-DR up-regulation. 
Our data suggest that HDAC inhibition increases the 
immunogenicity of TNBC, increasing PD-L1 and HLA-
DR expression, and reduces the immune system inhibitory 
compartment, decreasing CD4+ Foxp3+ Treg. This assumes 
a particular significance in the TNBC tumor characterized 
by an already existing, but masked immunogenicity that 
can be boosted by HDACi. On the other hand in ER+ 
tumors, characterized by a non-immunogenic behavior, the 
attempt to increase the tumor–immune system recognition 
by HDACi fails to succeed due to their intrinsic 
unresponsiveness and the absence of pre-exiting T cells 
infiltration in the tumors.
In conclusion, HDAC inhibition increases PD-L1 
and HLA-DR expression in TNBC and decreases Treg 
frequency, which when combined with PD-1 and CTLA-
4 blockade promotes TILs infiltration, tumor apoptosis, 
tumor regression and increased survival in mice (Figure 7). 
There are several possible explanations for these findings. 
The increased PD-L1 expression in TNBC could be either 
a) an isolated functional marker whose presence and up-
regulation indicate increased sensitivity to the PD-1/PD-
L1 pathway; which can be disrupted by the addition of 
checkpoint inhibitors or b) a marker of global changes in 
JAK/STAT induced gene expression, that in turn leads to 
increased sensitivity to checkpoint inhibitors seen in the 
TNBC model. In either scenario, the HDACi induction of 
PD-L1 can support the dependence of the tumor to the 
PD-1/PD-L1 pathway.
Overall, this study suggests that the combination 
of HDACi with immune checkpoint inhibitors identifies 
a novel therapeutic strategy for the treatment of TNBC.
MATERIALS AND METHODS
Reagents
VPA was purchased from Enzo Life Sciences. 
Stock solutions were prepared in sterile water. Entinostat 
(MS-275) and vorinostat were from Selleck Chemicals; 
panobinostat (LBH589) from Novartis International; 
5-Azacytidine (azacitidine) was from Sigma; GSK126 
was from Active Biochem. Stock solutions were prepared 
in DMSO. Monoclonal antibodies anti-mouse PD-1 
(clone RMP1-14, #BE0146) and anti-mouse CTLA-4 
(clone 9H10, #BE0131) were purchased from Bioxcell. 
Actinomicin D was purchased from Sigma Aldrich.
All media, serum, antibiotics, and glutamine were 
from Corning.
Primary antibodies (Abs) for western blotting: 
β-Actin-Ab (Sigma-Aldrich, cod.A5316), Programmed 
death-ligand 1 (PD-L1)-Ab (Abcam, cod.Ab58810); (PD-
L1)-Ab (cod.#13684), acetyl-H3-Ab (cod.#9649), PARP-Ab 
(cod.#9542) (Cell signaling Technology), and acetyl-H4-Ab 
(Millipore cod.06946). For IHC: monoclonal anti-mouse 
Ki67-Ab (Cell signaling Technology; cod.#12202), 
monoclonal anti-mouse CD4-Ab (Abcam, cod.Ab183685), 
anti-mouse CD8-Ab (eBioscience, clone 56-6.7). For 
immunofluorescence on fresh frozen tissues: anti-Foxp3-
efluor570 (eBioscience clone FJK-16s, #41-5773-80).
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Cell culture conditions
The MCF-7, MCF-7 TamR, T47D and SKBR3 
cells were maintained in DMEM, whereas 4T1, JC mouse 
breast cancer cells and MDA-MB231 in RPMI-1640 
medium. EMT6 were maintained in Waymouth MB 752/1 
media with 85% glutamine 2mM, 15% FBS. All cell lines 
were cultivated as described before [23]. MCF-7, T47D, 
SKBR3, MDA-MB231, JC and EMT6 were obtained from 
American Type Culture Collection, while 4T1 were kindly 
provided by Dr B. Hann. MDA-MB231, MCF-7 and T47D 
cells have been authenticated with a short tandem repeat 
profile on Promega PowerPlex16HS Assay at University 
of Arizona Genetics Core.
Western blot analysis
Cells were lysed in RIPA buffer (Sigma) and 
separated by SDS poly-acrylamide gel electrophoresis. 
Proteins were transferred to PVDF membranes and 
immunoblotted with the previous indicated antibodies. 
Immunoreactive bands were detected by enhanced 
chemiluminescence (GE Healthcare, cod. RPN2232), after 
the blots were probed with the appropriate horseradish 
peroxidase-linked IgG antibodies.
The signal intensities of a protein band and its 
surrounding background were scanned from images 
derived from at least two independent Western blot 
experiments for each cell line and quantified by using 
ImageJ software. Western blot relative quantifications of 
PD-L1 protein expression was normalized to β-actin and 
plotted as fold change.
Real-time quantitative PCR (qReal-Time PCR)
Total RNA was extracted from the cells by Trizol 
reagent according to the manufacturer’s instructions 
(Invitrogen). The reverse transcription-PCR (RT-PCR) 
assay was performed with iScript cDNA Synthesis Kit 
(Biorad).
Human PD-L1 (Hs01125301_m1), human 
GADD45a (Hs00169255_m1) and mouse PD-L1 
(Mm00452054_m1) mRNA expression were quantified 
by the 5′-nuclease method using StepOnePlus™ Real-
Time PCR Systems (Applied Biosystems). Each gene was 
tested in each cell line in triplicates in three independent 
experiments. The relative changes in gene expression were 
normalized to endogenous human or mouse β-actin gene 
expression levels respectively (Human ACTB and mouse 
Mm00607939_s1, Applied Biosystems) by the −2ΔΔCT 
method.
To investigate the mechanism by which vorinostat 
regulates PD-L1 mRNA, MDA-MB231 cells were 
untreated or treated with 5 μg/ml actinomycin D and/or 
vorinostat (1.5μM) up to 10 hours. PD-L1 and GADD45a 
mRNA expression was determined as described above. 
When analyzing the combination of vorinostat with other 
epigenetics drugs, MDA-MB231 cells were cultured in the 
presence of vorinostat 1.5μM in combination with azacitidine 
2μM and in combination with GSK126 300nM for 24 hours.
Immunofluorescent staining for PD-L1
MDA-MB231 or MCF-7 cells were seeded 30000 
cells/well. PD-L1 protein expression was evaluated after 
48 hours of treatment with vorinostat (1.5μM). Cells 
were stained for PD-L1 antibody (red, Cell signaling 
Technology cod.#86744) according to the manufacturer’s 
instructions. After secondary antibody incubation (Alexa 
Fluor 555, Invitrogen cod.A31572), slides were mounted 
with a DAPI (blue) mounting media (ProLong® Gold 
Antifade Mountant with DAPI, Life Technologies). Slides 
were next analyzed by microscopy (Zeiss AxioImager M1, 
Zeiss). Representative images show PD-L1+ cells with 20x 
and 40x magnification.
Co-culture experiments and flow cytometry 
analysis
3x105 MDA-MB231 cells were seeded in the 
presence or absence of 3x106 PBMCs cells freshly 
obtained by healthy donor blood (ratio 1:10). Tumor cells, 
PBMCs or co-cultured cells were treated or untreated with 
vorinostat (1.5μM) and collected after 24, 48 or 72 hours 
to perform multiparameter flow cytometry analysis. The 
following human Abs were used: anti-CD3 (#317324), 
anti-PD-1 (#329908), anti-CD45 (#304049), anti-CD8 
(#301039) Biolegend; anti-CD4 (#46-0047-42), anti-
CTLA-4 (#12-1529-42), anti-HLA-DR (#47-9956-41), 
anti-Foxp3 (#48-4777-42) eBioscience; anti-PD-L1 
(#558017), anti-Ki67 (#561277) BD Biosciences; Ghost 
Violet 510 viability dye (#13-0870 Tonbo Bioscence). 
Gates were determined using FMO and isotype control 
Ab staining. Data are expressed as mean of at least 
three separate experiments ± the standard error of the 
mean (± SEM). Similar experiments in co-culture were 
performed for MCF-7 and MCF-7 TamR cells. A similar 
flow cytometry panel was used for the dose-response 
experiment and to investigate the surface/intracellular 
position of PD-L1 on MDA-MB231 and MCF-7 TamR 
cells.
To investigate if vorinostat was able to modify the 
Treg compartment, 3x106 PBMCs cells, obtained from 
healthy donor blood, were treated or not with vorinostat 
(1.5μM) and collected after 24 and 48 hours to perform 
multiparameter flow cytometry analysis. The following 
human Abs were used: anti-CD3 (#56-0038-42), anti-
CD25 (#46-0257-42), anti-CD127 (#47-1278-42), 
anti-CTLA-4 (#12-1529-42), anti-Foxp3 (#48-4776-
42) eBioscience; anti-CD4 (#317438) and anti-CD8 
(#301042); Ghost Violet 510 viability dye (#13-0870 
Tonbo Bioscence). Data are expressed as mean of two 
separate experiments repeated on four healthy donors ± 
SEM.
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Data were acquired by an LSRFortessa (BD 
Biosciences) and analyzed using FlowJo software (Tree 
Star Inc.). To standardize voltages over time, Sphero Ultra 
Rainbow Beads (Spherotech) were used to calibrate and 
normalize to baseline intensity.
In vivo allograft studies
Four- to six-week-old female BALB/C mice 
(Harlan Laboratories) were acclimatized in the 
Laboratory Animal Resource Center at UCSF in 
accordance with the institutional guidelines (protocol 
AN136635). 4T1 cells (1x106) diluted in RPMI (without 
P/S and FBS) were implanted subcutaneously (s.c.) in 
the flank region of the mice. When the tumors became 
palpable, thirty-two mice were randomized into four 
experimental groups (n=8). Based on previous studies 
(Supplementary Figure 5 and [20, 23, 51]), the mice 
were treated intra peritoneal (i.p.) with 10 mg/kg anti–
PD-1 and anti–CTLA-4 antibodies (diluted in sterile 
PBS) on days 4, 6, 8, 10 post-tumor implantation and 
with vorinostat (100 mg/kg melted in DMSO and diluted 
daily in 10%DMSO+45%PEG-400+45%PBS) i.p. on 
days 5, 7, 9, 11. This schedule was repeated for a total of 
22 days. Control group mice were treated with vehicle 
(PBS/PEG-400) solution.
Tumor volume (mm3) was calculated as described 
before [23]. The mice were weighted three times/week 
while monitored daily for clinical signs and mortality. 
Mice were sacrificed when tumors reached a volume ≥ 
1cm3, a length ≥ 2cm or got ulcerated. At the end of the 
study, the remaining mice were sacrificed by exposure 
to CO2 followed by cervical dislocation. The percent 
change in the experimental groups was compared 
with that of the vehicle control group, as previously 
described [23].
RNA in situ hybridization of PD-L1
Mouse PD-L1 mRNAs were measured in 5μm 
FFPE 4T1 tumor samples by RNAscope assay (Advanced 
Cell Diagnostics, ACD) following the manufacturer’s 
instructions. Briefly, sections were deparaffinized, 
incubated with pretreatment reagents and target-retrieval 
was performed. FFPE samples were hybridized with 
m-CD274-probe (ACD) and hybridization signals were 
amplified with RNAscope 2.0 HD detection kit (Brown, 
ACD). Images were captured under a bright field at 40x 
magnification. Positive signals showed as brown punctate 
dots, were analyzed by scoring with ImageJ software. To 
check tissue RNA stability and non-specific hybridization, 
m-Ppib and DapB were used as positive and negative 
probes (ACD).
Histology, IHC, immunofluorescence analysis 
from mice tumor samples
At the end of treatment, at least two mice per 
group were sacrificed for pharmacodynamic studies. 
For immunohistochemical analysis, mitotic counts 
were performed on hematoxylin and eosin (H&E)-
stained sections and calculated as an average of two 
representative high power fields. Expression of Ki67, 
CD8 and CD4 was determined by IHC. Briefly, sections 
were incubated with primary antibody and then with 
SignalStain Boost IHC Detection Reagent (Cell signaling 
Technology) as secondary antibody for Ki67 and CD4, 
and with HRP Rat-on-mouse secondary antibody kit 
(Biocare) for CD8. Peroxidase reactivity was visualized 
using a 3,3’-diaminobenzidine (Vector Laboratories, cod.
SK4100). A single pathologist (G.K.) performed a blinded 
analysis of the slides for Ki67 and for the mitotic count.
Apoptosis was evaluated by TUNEL assay 
according to the manufacturer’s protocol (FragEL™ DNA 
Kit #QIA33, Calbiochem).
Foxp3 immunofluorescence staining was performed 
on fresh frozen tissues. Briefly 10μm thick tissue slides 
were fixed with a 1:1 solution of methanol/acetone, 
blocked with 3% BSA+1:200 mouse BD FC block (clone 
2.4G2, BD) in PBS. Slides were exposed to anti-Foxp3-
efluor570 antibody (red) and mounted with DAPI (blue). 
Representative images show Foxp3+ cells with 40x 
magnification.
Statistical analysis
Representative results from a single experiment 
of qReal-TimePCR (standard deviation of triplicates is 
shown in the figures), western blot, immunofluorescence, 
in situ hybridization and IHC are presented; additional 
experiments yielded similar results. Data are expressed as 
mean with standard deviation (± SD) or ± SEM indicated.
Appropriate statistical analyses were applied, 
assuming a normal sample distribution. Statistical 
significance in the differences of tumor growth in vivo 
was determined by the One-way Anova Test, followed 
by Bonferroni post-test (* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 
0.001; **** P ≤ 0.0001). Kaplan-Meier survival curves 
were analyzed with a log-rank test (* P ≤ 0.05; *** P ≤ 
0.001; Ns: non significant). Mitotic count differences, 
RNAscope, CD4, CD8 IHC, Foxp3 immunofluorescence, 
flow cytometry experiments and TUNEL assay 
results were analyzed by One-way Anova followed 
by Bonferroni post-test (* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 
0.001; **** P ≤ 0.0001; Ns: non significant). All statistical 
evaluations were performed with Prism software 
(GraphPad Software, Inc).
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Ethics approval
Animal studies were conducted according to a 
UCSF Laboratory Animal Resource Center (LARC) 
protocol (AN136635). This protocol was approved by 
the UCSF Institutional Animal Care and Use Committee 
(IACUC) accredited by Association for Assessment and 
Accreditation of Laboratory Animal Care International 
(#001084).
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